328 related articles for article (PubMed ID: 17483547)
1. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
2. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
5. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
6. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
8. New PCR ribotypes of Clostridium difficile detected in children in Brazil: prevalent types of Clostridium difficile in Brazil.
Alcides AP; Brazier JS; Pinto LJ; Balassiano IT; Boente RF; de Paula GR; Ferreira EO; Avelar KE; Miranda KR; Ferreira MC; Domingues RM
Antonie Van Leeuwenhoek; 2007 Jul; 92(1):53-9. PubMed ID: 17252315
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of Clostridium difficile in Scotland.
Wiuff C; Brown DJ; Mather H; Banks AL; Eastaway A; Coia JE
J Infect; 2011 Apr; 62(4):271-9. PubMed ID: 21300104
[TBL] [Abstract][Full Text] [Related]
10. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH
J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
12. Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106.
Ratnayake L; McEwen J; Henderson N; Nathwani D; Phillips G; Brown D; Coia J
J Hosp Infect; 2011 Nov; 79(3):242-7. PubMed ID: 21864938
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH
J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Clostridium difficile-associated disease in North America and Europe.
Kuijper EJ; Coignard B; Tüll P; ; ;
Clin Microbiol Infect; 2006 Oct; 12 Suppl 6():2-18. PubMed ID: 16965399
[TBL] [Abstract][Full Text] [Related]
15. [Life-threatening infections with a new strain of Clostridium difficile].
Krausz S; Bessems M; Boermeester MA; Kuijper EJ; Visser CE; Speelman P
Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2081-6. PubMed ID: 16201595
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of Clostridium difficile PCR ribotype 027 in the Netherlands 2005-present and the emergence of other subtypes].
Notermans DW; van der Kooi TI; Goorhuis A; Debast SB; van Benthem BH; Kuijper EJ
Ned Tijdschr Geneeskd; 2008 Aug; 152(35):1937-40. PubMed ID: 18808085
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
Huang H; Wu S; Wang M; Zhang Y; Fang H; Palmgren AC; Weintraub A; Nord CE
Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757
[TBL] [Abstract][Full Text] [Related]
18. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm.
Huang H; Fang H; Weintraub A; Nord CE
Clin Microbiol Infect; 2009 Dec; 15(12):1170-3. PubMed ID: 19624517
[TBL] [Abstract][Full Text] [Related]
19. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands.
Goorhuis A; Van der Kooi T; Vaessen N; Dekker FW; Van den Berg R; Harmanus C; van den Hof S; Notermans DW; Kuijper EJ
Clin Infect Dis; 2007 Sep; 45(6):695-703. PubMed ID: 17712752
[TBL] [Abstract][Full Text] [Related]
20. New trends in Clostridium difficile virulence and pathogenesis.
Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
